The Global Market for Adjunctive Therapies in Cancer
Published By: Kalorama Information
May 2002
R566-0021
Online Download $2,625.00 Hard Copy Mail Delivery $2,625.00 (Subject to Shipping Charges) Global Site License $5,250.00 Online Download plus 1 Hard Copy $2,875.00 (Subject to Shipping Charges)
Description

Special Offer. Now 25% off the original price of $3500. The Global Market for Adjunctive Therapies in Cancer provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat and manage symptoms in cancer patients. Market information is available for the years 1996 to 2006, with the focus year 2001. Overview and product descriptions of general adjunctive therapy segments are covered, including:
- antinauseants and antiemetics
- pain management
- blood modifiers
- infection control; and
- other therapies.
The study covers issues and trends affecting the market, research and developments, demographics, cancer statistics and more. Profiles of major market participants are included.
|
Table of Contents
Chapter One: Executive Summary
Introduction
Scope and Methodology
Size and Growth Of The Market
Issues and Trends Affecting The Global Market
Leading Competitors
Chapter Two: Introduction
Overview of Cancer
- Biology of Cancer
- Treatments and Symptoms
Types of Products and Administration
Demographics, Prevalence, Incidence, Mortality
Chapter Three: Issues and Trends
Overview
Geographical Trends
Regulatory Authorities
- Clinical Trials
- New Indications
Direct-To-Consumer Advertising
Lifestyle and Social Issues
Barriers To Adjunctive Therapies
Drug Delivery Advancements
Pain Management Measures
Oxycontin Issues
Cancer-Related Fatigue Issues
Individualized Chemotherapy
Chemotherapy and Memory Loss
Chapter Four: Antinauseants and Antiemetics
Overview
Products
- Serotonin Receptor Antagonists
- Phenothiazines
- Metoclopramide and Other Drugs
Drug Delivery Methods For Antinauseants and Antiemetics
Research And Development
Market Overview By Geographic Region
- United States
- Europe
- Japan
- Rest of World
Competitive Analysis
Chapter Five: Pain Management
Overview
- Pain Pathways
- Primary Cancer Pain
- Breakthrough Cancer Pain
- Cancer Pain Delivery Methods
Description of Products
- Primary Cancer Pain Medications
- Breakthrough Cancer Pain Medications
Research and Development
Market Overview By Geographic Region
- United States
- Europe
- Japan
- Rest of World
Competitive Analysis
Chapter Six: Biological Response Modifiers
Overview
Description of Products
- Hematopoietic Growth Factors
- Cytomodulatory Agents
Research And Development
Market Overview By Geographic Region
- United States
- Europe
- Japan
- Rest of World
Competitive Analysis
Chapter Seven: Infection Control
Overview
Description of Products
- Anti-Infectives
- Antifungals
Research And Development
Market Overview By Geographic Region
- United States
- Europe
- Japan
- Rest of World
Competitive Analysis
Chapter Eight: Other Adjunctive Therapies
Overview
Description of Products
- Fatigue
- Anorexia/Cachexia/Weight Loss
- Diarrhea
- Constipation
- Hair Loss
Research And Development
Market Overview By Geographic Region
- United States
- Europe
- Japan
- Rest of World
Competitive Analysis
Chapter Nine: Total Market Size and Forecast
Overview
Total Market Size and Forecast
- Market By Segment
- Market By Region
Competitive Analysis
Market Analysis
Chapter Ten: Company Profiles
Introduction
Competitive Summary
Abbott Laboratories
Amgen, Inc.
Aventis
Bayer Corporation
Chugai Pharmaceutical Company Ltd.
Eli Lilly & Company
Glaxosmithkline Plc
Johnson & Johnson
Kirin Brewery Company Ltd.
Knoll Pharmaceuticals Company (Abbott Laboratories)
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
Roche Group
Roxane Laboratories, Inc.
Appendix: Company Directory
List of Exhibits
Table 1-1: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2001
Table 1-2: The Global Market for Adjunctive Therapies in Cancer by Type, 1996-2006
Figure 1-1: The Global Market for Adjunctive Therapies in Cancer Revenues by Type 1996-2006
Figure 1-2: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 1996-2006
Table 2-1: List of Cancers
Table 2-2: Side Effects Associated with Chemotherapy
Table 2-3: Side Effects Associated with Radiation Therapy
Table 2-4: Population by Country 1996-2006
Figure 2-1: Population by Significant Country 1996, 2001, 2006
Table 2-5: Cancer Prevalence by Country 1996-2001
Figure 2-2: Cancer Prevalence by Country 1996-2001
Table 2-6: Cancer Incidence by Country 1996-2001
Figure 2-3: Cancer Incidence by Country 1996-2001
Table 2-7: Cancer Deaths by Country 1996-2001
Figure 2-4: Cancer Deaths by Country
Table 2-8: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2001
Table 2-9: Cancer Incidence by Type and Country 2001
Table 2-10: Cancer Deaths by Type and Country 200141
Figure 4-1: Incidence of Emesis in Cancer Patients
Table 4-1: Chemotherapy Agents and Level of Emetic Potential
Table 4-2: Selected Prescription Antinauseants, Antiemetics and Others with Antiemetic Properties by Available Delivery Method
Table 4-3: Antinauseants and Antiemetics in Development for Treatment of Cancer related Nausea and Vomiting
Table 4-4: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Figure 4-2: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Table 4-5: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics by Geographic Region 1996-2006
Table 4-6: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics Share of Global Market by Geographic Region 1996-2006
Figure 4-3: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics, by Geographic Region, 1996-2006
Figure 4-4: The Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics, Share by Geographic Region 2001
Table 4-7: U.S. Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Figure 4-5: U.S. Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Table 4-8: European Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Figure 4-6: European Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Table 4-9: Japanese Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Figure 4-7: Japanese Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Table 4-10: Rest of World Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Figure 4-8: Rest of World Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics 1996-2006
Table 4-11: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics
Figure 4-9: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Antinauseants and Antiemetics
Figure 5-1: Incidence of Pain in Cancer Patients
Table 5-1: The World Health Organization Three-Step Analgesic Ladder
Table 5-2: Selected Prescription Non-Narcotic Analgesics by Available Delivery Method
Table 5-3: Selected Over-the-Counter Non-Narcotic Analgesics by Available Delivery Method
Table 5-4: Selected Prescription Narcotic Analgesics by Available Delivery Method
Table 5-5: Selected Prescription Antidepressants Used for Cancer Pain by Available Delivery Method
Table 5-6: Selected Prescription Anticonvulsants Used for Cancer Pain by Available Delivery Method
Table 5-7: Selected Prescription Corticosteroids Used for Cancer Pain by Available Delivery Method
Table 5-8: Selected Prescription Bisphosphonates and Calcitonins Used for Cancer Pain by Available Delivery Method
Table 5-9: Selected Prescription Radiopharmacuticals Used for Cancer Pain by Available Delivery Method
Table 5-10: Pain Management Products in Development for Treatment of Cancer Related Pain
Table 5-11: The Global Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Figure 5-2: The Global Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Table 5-12: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Geographic Region 1996-2006
Table 5-13: The Global Market for Adjunctive Therapies in Cancer: Pain Management Products Share of Global Market by Geographic Region 1996-2006
Figure 5-3: The Global Market for Adjunctive Therapies in Cancer: Pain Management by Geographic Region 1996-2006
Figure 5-4: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Percent and Geographic Region 2001
Table 5-14: The Global Market for Adjunctive Therapies in Cancer: Pain Management by Pain Type 1996-2006
Table 5-15: The Global Market for Adjunctive Therapies in Cancer: Pain Management Market Share by Pain Type 1996-2006
Figure 5-5: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Pain Type, 1996-2006
Figure 5-6: The Global Market for Adjunctive Therapies in Cancer: Pain Management, by Pain Type 2001
Table 5-16: U.S. Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Figure 5-7: U.S. Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Table 5-17: European Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Figure 5-8: European Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Table 5-18: Japanese Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Figure 5-9: Japanese Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Table 5-19: Rest of World Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Figure 5-10: Rest of World Market for Adjunctive Therapies in Cancer: Pain Management 1996-2006
Table 5-20: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Pain Management 2001
Figure 5-11: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer: Pain Management, 2001
Figure 6-1: Frequency of Bone Marrow Suppression in Cancer Patients
Table 6-1: Selected Biological Response Modifiers, and Available Delivery Method
Table 6-2: Biological Response Modifiers in Development for Treatment of Cancer related Infection
Table 6-3: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Figure 6-2: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers
Table 6-4: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers by Geographic Region 1996-2006
Table 6-5: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers Share by Geographic Region, 1996-2006
Figure 6-3: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers by Geographic Region 1996-2006
Figure 6-4: The Global Market for Adjunctive Therapies in Cancer: Biological Response Modifiers Share by Geographic Region 2001
Table 6-6: The U.S. Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Figure 6-5: The U.S. Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Table 6-7: European Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Figure 6-6: European Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Table 6-8: Japanese Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Figure 6-7: Japanese Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Table 6-9: Rest of World Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Figure 6-8: Rest of World Market for Adjunctive Therapies in Cancer: Biological Response Modifiers 1996-2006
Table 6-10: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer Biological Response Modifiers 2001
Figure 6-9: Leading Suppliers’ Shares of the Global Market for Adjunctive Therapies in Cancer Biological Response Modifiers 2001
Table 7-1: Common Infection Sites and Organisms
Figure 7-1: Frequency of Infection in Cancer Patients
Table 7-2: Selected Prescription Anti-infective Agents and Available Delivery Methods
Table 7-3: Selected Prescription Antifungals and Available Delivery Method
Table 7-4: Anti-Infective Agents and Antifungals in Development for Treatment of Cancer related Infection
Table 7-5: The Global Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Figure 7-2: The Global Market for Adjunctive Therapies in Cancer: Infection Control, 1996-2006
Table 7-6: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Geographic Region 1996-2006
Table 7-7: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Geographic Region 1996-2006
Figure 7-3: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Geographic Region 1996-2006
Figure 7-4: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Geographic Region 2001
Table 7-8: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Type 1996-2006
Table 7-9: The Global Market for Adjunctive Therapies in Cancer: Infection Control Share by Type 1996-2006
Figure 7-5: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Product Type 1996-2006
Figure 7-6: The Global Market for Adjunctive Therapies in Cancer: Infection Control by Product Type 2001
Table 7-10: U.S. Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Figure 7-7: U.S. Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Table 7-11: European Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Figure 7-8: European Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Table 7-12: Japanese Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Figure 7-9: Japanese Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Table 7-13: Rest of World Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Figure 7-10: Rest of World Market for Adjunctive Therapies in Cancer: Infection Control 1996-2006
Table 7-14: Leading Suppliers’ Share of the Global Market for Adjunctive Therapies in Cancer: Infection Control 2001
Figure 7-11: Leading Suppliers’ Share of the Global Market for Adjunctive Therapies in Cancer: Infection Control 2001
Figure 8-1: Frequency of Fatigue in Cancer Patients
Figure 8-2: Incidence of Anorexia/Cachexia/Weight Loss in Cancer Patients
Figure 8-3: Incidence of Diarrhea in Cancer Patients
Figure 8-4: Incidence of Constipation in Cancer Patients
Table 8-1: Selected Chemotherapy Agents and Level of Hair Loss Potential
Figure 8-5: Frequency of Hair Loss in Cancer Patients
Figure 8-6: Prevalence of Various Conditions in Cancer Patients
Table 8-2: Selected Prescription and Non-prescription Products to Minimize Symptoms of Fatigue in Cancer Patients and Available Delivery Method
Table 8-3: Selected Prescription Products for the Treatment of Anorexia/Cachexia in Cancer Patients and Available Delivery Method
Table 8-4: Selected Prescription and Non-prescription Products for the Treatment of Diarrhea in Cancer Patients and Available Delivery Method
Table 8-5: Selected Prescription and Non-prescription Products for the Treatment of Constipation in Cancer Patients and Available Delivery Method
Table 8-6: Other Adjunctive Therapies in Development for Treatment of Cancer
Table 8-7: The Global Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Figure 8-7: The Global Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Table 8-8: The Global Market for Adjunctive Therapies in Cancer: Other Therapies, by Geographic Region, 1996-2006
Table 8-9: The Global Market for Adjunctive Therapies in Cancer Other Therapies Distribution by Geographic Region 1996-2006
Figure 8-8: The Global Market for Adjunctive Therapies in Cancer: Other Therapies by Geographic Region 1996-2006
Figure 8-9: The Global Market for Adjunctive Therapies in Cancer: Other Therapies Distribution by Geographic Region 2001
Table 8-10: U.S. Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Figure 8-10: U.S. Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Table 8-11: European Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Figure 8-11: European Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Table 8-12: Japanese Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Figure 8-12: Japanese Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Table 8-13: Rest of World Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Figure 8-14: Rest of World Market for Adjunctive Therapies in Cancer: Other Therapies 1996-2006
Table 9-1: The Global Market for Adjunctive Therapies in Cancer by Type, 1996-2006
Table 9-2: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 1996-2006
Figure 9-1: The Global Market for Adjunctive Therapies in Cancer Revenues by Type 1996-2006
Figure 9-2: The Global Market for Adjunctive Therapies in Cancer by Type and Percent Distribution, 1996-2006
Figure 9-3: The Global Market for Adjunctive Therapies in Cancer Distribution by Type 2001
Table 9-3: The Global Market for Adjunctive Therapies in Cancer by Geographical Region, 1996-2006
Table 9-4: The Global Market for Adjunctive Therapies in Cancer Distribution by Geographical Region 1996-2006
Figure 9-4: The Global Market for Adjunctive Therapies in Cancer Revenues by Geographical Region 1996-2006
Figure 9-5: The Global Market for Adjunctive Therapies in Cancer by Geographical Region and Percent Distribution, 1996-2006
Figure 9-6: The Global Market for Adjunctive Therapies in Cancer by Percent and Geographical Region, 2001
Table 9-5: Leading Suppliers, Products, and Segments of Participation 2001
|
Order Form * Please reference product number R566-0021 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|